Soliris recommended for approval in the EU by CHMP for children and adolescents with gMG
The first-in-class C5 inhibitor reduced disease severity and symptoms with sustained improvements over 26 weeks in Phase III…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Jun 23
The first-in-class C5 inhibitor reduced disease severity and symptoms with sustained improvements over 26 weeks in Phase III…
26 Jun 23
Litfulo is said to be the first and only treatment approved by the FDA for adolescents with severe…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Jun 23
Under the partnership, both parties will start a therapeutic nutrition program that will use data from CGM technology…
26 Jun 23
Additionally, Brii Bio will acquire exclusive global rights for the development and commercialisation of the novel lipopeptide BRII-693…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Jun 23
The partnership intends to generate new data endpoints via a patient-centric and unobtrusive monitoring approach with a focus…
26 Jun 23
Embracing the "green pharma" philosophy, Lysando's Artilysin molecules effectively target resistant pathogens while minimizing environmental, wastewater, and food…
26 Jun 23
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative…
23 Jun 23
Elevidys (delandistrogene moxeparvovec-rokl) is an adeno-associated virus (AAV)-based gene therapy indicated for the treatment of ambulatory paediatric patients,…
23 Jun 23
The merged firm will concentrate on developing Tourmaline's TOUR006 programme, an anti-IL-6 antibody to treat thyroid eye disease…
23 Jun 23
Lunaphore’s spatial biology portfolio uses precision microfluidic technology to find hyperplex proteomic and transcriptomic biomarkers in tumours and…